Ten years of subcutaneous defibrillator therapy: Consolidated clinical evidence and future perspectives

Abstract

AbstractThe subcutaneous implantable cardioverter defibrillator (S‐ICD) was developed as an alternative to the traditional transvenous implantable cardioverter defibrillator (TV‐ICD), aiming to provide easier implantation, simplified detection algorithm of malignant ventricular arrhythmias and prevention from placing components in the cardiovascular system. The S‐ICD is implanted subcutaneously or intramuscularly with the generator placed in the left midaxillary line and the lead tunneled subcutaneously in the left para‐sternal region. Preimplant electrocardiogram screening is recommended to prevent implantation in patients at high risk of T wave over‐sensing. Currently, the S‐ICD is unsuitable for patients requiring pacing or cardiac resynchronization. Since the beginning, the S‐ICD underwent extensive preclinical investigation until the first prospective multicentre trial demonstrating high efficacy and safety led to market release. While earlier studies focused on younger patients with higher ejection fraction, more recent studies showed favorable outcomes even in patients with comorbidities similar to those typically observed in patients receiving TV‐ICD. The development of second and third generation devices has contributed to reduce inappropriate shocks and overcome previous limitations. The aim of this paper is to review the evidence in the literature over the past decade supporting S‐ICD as a valid alternative to TV‐ICD in terms of safety and efficacy, highlighting the improvements in technology, as well as outcomes.